2017 Buyer’s Guide

This buyer’s guide offers a searchable, comprehensive listing of the FDA-approved interventional devices available in the United States.

Cardinal Health Announces Strategic Distribution Agreements in International Markets

 

October 31, 2016—Cardinal Health announced several new strategic distribution agreements that will enable Cordis, Cardinal Health’s interventional vascular business, to expand its product portfolio in select countries globally. These distribution agreements are related to coronary stents and percutaneous transluminal coronary angioplasty (PTCA) balloon catheters in Cordis’ portfolio of products that support the treatment of patients undergoing percutaneous coronary intervention. The agreements are:

  • An expansion of its current distribution agreement with Biosensors International Group, Ltd. that will enable Cordis to be the exclusive distributor for Biosensors’ coronary interventional products in Japan. Cordis will now distribute Biosensors’ coronary stent portfolio in approximately 27 countries in Europe, the Middle East, and Africa (EMEA), in addition to Japan, Australia, and New Zealand.
  • A distribution agreement with Kaneka Corporation that enables Cordis to distribute Kaneka’s PTCA balloon catheters in EMEA, and select countries in Asia Pacific and Latin America. In Japan, Korea, Australia, and New Zealand, Cordis will sell versions of Kaneka’s PTCA balloon catheters under the names of Neon and Neon NC. In China, Cordis will be the sole distributor of Ikazuchi Rev and Fortis II, under Kaneka’s brand. Upon Kaneka receiving CE Mark approval in Europe and other regulatory clearances in EMEA, China, and select Latin American countries, Cordis will begin to sell the Ikazuchi Zero and Raiden 3 PTCA balloons under the Kaneka brand name.
  • A distribution agreement with Meril Life Sciences Pvt. Ltd. that enables Cordis to sell Meril’s Mozec and Mozec NC Rx PTCA balloon dilatation catheters in the United States and Canada.
  • A strategic agreement with Tryton Medical Inc. Cardinal advised that it is committed to a long-term relationship in the United States where Tryton is currently seeking regulatory approval for their coronary side branch stent. Tryton also announced the agreement on October 28.
 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.